Rocket Pharmaceuticals is trading 10.13% up today at $3.42 following a positive Phase 2 safety update for its Danon disease treatment candidate, RP-A501.
- The company reported that the first three patients treated under a modified protocol showed good tolerability, which serves as the primary catalyst for the stock's gain.
- Broader market strength is providing additional support to the move, with the S&P 500, Nasdaq, and Dow all trading higher in a risk-on session.